| # | Title | Journal | Year | Citations |
|---|
| 1 | EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update | Annals of the Rheumatic Diseases | 2017 | 3,366 |
| 2 | Rheumatoid arthritis | Nature Reviews Disease Primers | 2018 | 1,441 |
| 3 | Efficacy of biological disease-modifying antirheumatic drugs: a systematic literature review informing the 2013 update of the EULAR recommendations for the management of rheumatoid arthritis | Annals of the Rheumatic Diseases | 2014 | 270 |
| 4 | Scoring ultrasound synovitis in rheumatoid arthritis: a EULAR-OMERACT ultrasound taskforce — Part 1: definition and development of a standardised, consensus-based scoring system | RMD Open | 2017 | 250 |
| 5 | A phase III randomised, double-blind, parallel-group study comparing SB4 with etanercept reference product in patients with active rheumatoid arthritis despite methotrexate therapy | Annals of the Rheumatic Diseases | 2017 | 201 |
| 6 | Native joint-resident mesenchymal stem cells for cartilage repair in osteoarthritis | Nature Reviews Rheumatology | 2017 | 173 |
| 7 | Consensus-based recommendations for the use of biosimilars to treat rheumatological diseases | Annals of the Rheumatic Diseases | 2018 | 173 |
| 8 | Predicting the development of clinical arthritis in anti-CCP positive individuals with non-specific musculoskeletal symptoms: a prospective observational cohort study | Annals of the Rheumatic Diseases | 2015 | 169 |
| 9 | Evidence of NLRP3-inflammasome activation in rheumatoid arthritis (RA); genetic variants within the NLRP3-inflammasome complex in relation to susceptibility to RA and response to anti-TNF treatment | Annals of the Rheumatic Diseases | 2014 | 166 |
| 10 | Development of a health index in patients with ankylosing spondylitis (ASAS HI): final result of a global initiative based on the ICF guided by ASAS | Annals of the Rheumatic Diseases | 2015 | 161 |
| 11 | The contribution of musculoskeletal disorders in multimorbidity: Implications for practice and policy | Best Practice and Research in Clinical Rheumatology | 2017 | 99 |
| 12 | The problem in differentiation between psoriatic-related polyenthesitis and fibromyalgia | Rheumatology | 2018 | 93 |
| 13 | Long-term efficacy and safety in patients with rheumatoid arthritis continuing on SB4 or switching from reference etanercept to SB4 | Annals of the Rheumatic Diseases | 2017 | 90 |
| 14 | Predicting and managing primary and secondary non-response to rituximab using B-cell biomarkers in systemic lupus erythematosus | Annals of the Rheumatic Diseases | 2017 | 90 |
| 15 | COVID-19 vaccination and antirheumatic therapy | Rheumatology | 2021 | 89 |
| 16 | The Efficacy and Safety of Subcutaneous Clazakizumab in Patients With Moderate‐to‐Severe Rheumatoid Arthritis and an Inadequate Response to Methotrexate: Results From a Multinational, Phase IIb, Randomized, Double‐Blind, Placebo/Active‐Controlled, Dose‐Ranging Study | Arthritis and Rheumatology | 2015 | 86 |
| 17 | Comparing the effects of tofacitinib, methotrexate and the combination, on bone marrow oedema, synovitis and bone erosion in methotrexate-naive, early active rheumatoid arthritis: results of an exploratory randomised MRI study incorporating semiquantitative and quantitative techniques | Annals of the Rheumatic Diseases | 2016 | 85 |
| 18 | Prediction of autoimmune connective tissue disease in an at-risk cohort: prognostic value of a novel two-score system for interferon status | Annals of the Rheumatic Diseases | 2018 | 79 |
| 19 | Recent advances in ankylosing spondylitis: understanding the disease and management | F1000Research | 2018 | 77 |
| 20 | Update on novel pharmacological therapies for osteoarthritis | Therapeutic Advances in Musculoskeletal Disease | 2019 | 75 |
| 21 | How do people with knee osteoarthritis use osteoarthritis pain medications and does this change over time? Data from the Osteoarthritis Initiative | Arthritis Research and Therapy | 2013 | 66 |
| 22 | Brief Report: Magnetic Resonance Imaging Assessment of Axial Psoriatic Arthritis: Extent of Disease Relates to HLA–B27 | Arthritis and Rheumatism | 2013 | 59 |
| 23 | Autoantibodies to Posttranslationally Modified Type II Collagen as Potential Biomarkers for Rheumatoid Arthritis | Arthritis and Rheumatism | 2013 | 59 |
| 24 | 52-week results of the phase 3 randomized study comparing SB4 with reference etanercept in patients with active rheumatoid arthritis | Rheumatology | 2017 | 59 |
| 25 | Transition phase towards psoriatic arthritis: clinical and ultrasonographic characterisation of psoriatic arthralgia | RMD Open | 2019 | 56 |
| 26 | New horizons in osteoarthritis | Age and Ageing | 2013 | 49 |
| 27 | A phase I pharmacokinetics trial comparing PF‐05280586 (a potential biosimilar) and rituximab in patients with active rheumatoid arthritis | British Journal of Clinical Pharmacology | 2016 | 48 |
| 28 | T cell subsets: an immunological biomarker to predict progression to clinical arthritis in ACPA-positive individuals | Annals of the Rheumatic Diseases | 2016 | 46 |
| 29 | Haematopoietic stem cell transplantation for poor-prognosis systemic sclerosis | Rheumatology | 2015 | 35 |
| 30 | Comprehensive disease control (CDC): what does achieving CDC mean for patients with rheumatoid arthritis? | Annals of the Rheumatic Diseases | 2015 | 33 |
| 31 | Efficacy and Safety of Subcutaneous Golimumab in Methotrexate‐Naive Patients With Rheumatoid Arthritis: Five‐Year Results of a Randomized Clinical Trial | Arthritis Care and Research | 2016 | 32 |
| 32 | Axial Involvement in Psoriatic Arthritis cohort (AXIS): the protocol of a joint project of the Assessment of SpondyloArthritis international Society (ASAS) and the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) | Therapeutic Advances in Musculoskeletal Disease | 2021 | 30 |
| 33 | The Changing Face of Clinical Trials in Psoriatic Arthritis | Current Rheumatology Reports | 2017 | 29 |
| 34 | Is a questionnaire and radiograph-based follow-up model for patients with primary hip and knee arthroplasty a viable alternative to traditional regular outpatient follow-up clinic? | Bone and Joint Journal | 2016 | 26 |
| 35 | Current concepts and unmet needs in psoriatic arthritis | Clinical Rheumatology | 2018 | 26 |
| 36 | The effects of sprifermin on symptoms and structure in a subgroup at risk of progression in the FORWARD knee osteoarthritis trial | Seminars in Arthritis and Rheumatism | 2021 | 24 |
| 37 | Primary myocardial disease in scleroderma—a comprehensive review of the literature to inform the UK Systemic Sclerosis Study Group cardiac working group | Rheumatology | 2017 | 23 |
| 38 | Real-world single centre use of JAK inhibitors across the rheumatoid arthritis pathway | Rheumatology | 2021 | 23 |
| 39 | Extension Study of PF‐05280586, a Potential Rituximab Biosimilar, Versus Rituximab in Subjects With Active Rheumatoid Arthritis | Arthritis Care and Research | 2018 | 22 |
| 40 | Subjective and Objective Measures of Dryness Symptoms in Primary Sjögren's Syndrome: Capturing the Discrepancy | Arthritis Care and Research | 2017 | 18 |
| 41 | Anatomical location of erosions at the metatarsophalangeal joints in patients with rheumatoid arthritis | Rheumatology | 2014 | 17 |
| 42 | Twenty-eight-week results from the REALISTIC phase IIIb randomized trial: efficacy, safety and predictability of response to certolizumab pegol in a diverse rheumatoid arthritis population | Arthritis Research and Therapy | 2015 | 16 |
| 43 | B Cell Therapies, Approved and Emerging: a Review of Infectious Risk and Prevention During Use | Current Rheumatology Reports | 2015 | 16 |
| 44 | The Role of the Microbiome in Driving RA-Related Autoimmunity | Frontiers in Cell and Developmental Biology | 2020 | 16 |
| 45 | Outcome Measures in Psoriatic Arthritis | Rheumatic Disease Clinics of North America | 2015 | 15 |
| 46 | Focussing on the foot in psoriatic arthritis: pathology and management options | Expert Review of Clinical Immunology | 2018 | 14 |
| 47 | Cardiovascular outcomes of patients with rheumatoid arthritis prescribed disease modifying anti-rheumatic drugs: a review | Expert Opinion on Drug Safety | 2018 | 14 |
| 48 | Medial stabilised total knee arthroplasty achieves comparable clinical outcomes when compared to other TKA designs: a systematic review and meta-analysis of the current literature | Knee Surgery, Sports Traumatology, Arthroscopy | 2022 | 13 |
| 49 | Can we improve the performance and reporting of investigator-initiated clinical trials? Rheumatoid arthritis as an example: Table 1 | Annals of the Rheumatic Diseases | 2014 | 11 |
| 50 | Developing a standardized approach to virtual clinic follow-up of hip and knee arthroplasty | Bone and Joint Journal | 2019 | 11 |
